Literature DB >> 11813884

Expression of E-cadherin-catenin complex in human benign schwannomas.

M Hasegawa1, N Muramatsu, Y Tohma, K Fukaya, H Fujisawa, Y Hayashi, O Tachibana, S Kida, J Yamashita, K Saito.   

Abstract

The Ca2+-dependent cell adhesion molecule E-cadherin has been known to express in normal and reactive Schwann cells in rodents, and to play an important role in Schwann cell-Schwann cell adhesion and maintenance of peripheral nervous tissue architecture. However, little is known about expression of E-cadherin in schwannomas. The aim of the present study was to investigate the cellular expression and localization of E-cadherin, and its associated protein, alpha E-, alpha N- and beta-catenins in human schwannomas, which are supposed to derive from Schwann cells. We tested the hypothesis that these proteins might show an altered expression/distribution in schwannoma cells which correlates with their neoplastic behavior, including sparse cell-cell contact, as seen those in meningiomas and various carcinomas. In human schwannomas, however, E-cadherin, alpha E-catenin, and beta-catenin were detected by western blotting and immunohistochemistry, whereas alpha N-catenin was not. Immunoprecipitation using anti-E-cadherin antibody resulted in alpha E-catenin forming a complex with E-cadherin. SSCP analysis revealed no mutations in the transmembrane domain or in intracellular catenin-binding site of E-cadherin. These data suggest that the E-cadherin-alpha E-catenin complex is well preserved in human schwannoma cells, which is compatible with its benign behavior, and these molecules might be used as additional cell markers of Schwann cell-derived tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11813884     DOI: 10.14670/HH-17.39

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  1 in total

1.  Analysis of cytogenetic aberrations in sporadic vestibular schwannoma by comparative genomic hybridization.

Authors:  Dimitrios Koutsimpelas; Uwe Felmeden; Wolf J Mann; Jürgen Brieger
Journal:  J Neurooncol       Date:  2010-09-26       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.